{"id":40076,"date":"2025-08-26T13:45:31","date_gmt":"2025-08-26T05:45:31","guid":{"rendered":"https:\/\/flcube.com\/?p=40076"},"modified":"2025-08-26T13:45:31","modified_gmt":"2025-08-26T05:45:31","slug":"wusheng-erlunbao-sinopharms-first%e2%80%91of%e2%80%91its%e2%80%91kind-hexavalent-rotavirus-vaccine-receives-nmpa-approval","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40076","title":{"rendered":"Wusheng\u202fErlunbao: Sinopharm\u2019s First\u2011of\u2011Its\u2011Kind Hexavalent Rotavirus Vaccine Receives NMPA Approval"},"content":{"rendered":"\n<p>The Wuhan Institute of Biological Products Co., Ltd., a subsidiary of Sinopharm Group Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/1099:HKG\">HKG: 1099<\/a>), has secured National Medical Products Administration (NMPA) clearance for its oral hexavalent reassortant rotavirus attenuated live vaccine\u2014traded under the name <strong>Wusheng\u202fErlunbao<\/strong>. This marks the first and most comprehensive rotavirus vaccine in the world, classified as a Category\u202f1 preventive biological product in China.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-why-wusheng-erlunbao-is-a-game-changer\">Why Wusheng\u202fErlunbao Is a Game Changer<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Hexavalent Coverage<\/strong>: Protects against six clinically relevant serotypes\u2014G1, G2, G3, G4, G8, and G9\u2014providing broader immunity than existing two\u2011 or three\u2011valent vaccines.<\/li>\n\n\n\n<li><strong>Oral Administration<\/strong>: Designed for infants aged 6 to 36\u202fweeks, the vaccine offers a child\u2011friendly delivery route that promotes high uptake and compliance.<\/li>\n\n\n\n<li><strong>Robust Safety &amp; Efficacy<\/strong>: Early clinical studies demonstrate a favorable safety profile and strong immunogenicity, reinforcing the vaccine\u2019s potential to reduce rotavirus\u2011related morbidity and mortality among young children.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-global-impact-on-infant-health\">Global Impact on Infant Health<\/h3>\n\n\n\n<p>Rotavirus remains the leading cause of severe diarrhea in children under five worldwide and a major contributor to infant mortality in developing countries. By offering comprehensive protection, Wusheng\u202fErlunbao could dramatically lower the incidence of rotavirus gastroenteritis, easing the burden on healthcare systems and improving child survival rates.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-next-steps-for-sinopharm\">Next Steps for Sinopharm<\/h3>\n\n\n\n<p>With regulatory approval in hand, Wuhan Institute of Biological Products is poised to scale production, pursue market entry in China, and explore international distribution. The company\u2019s strategic partnership with Sinopharm\u2019s extensive distribution network positions Wusheng\u202fErlunbao for rapid deployment and widespread adoption, potentially setting a new standard for rotavirus prevention globally.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Wuhan Institute of Biological Products Co., Ltd., a subsidiary of Sinopharm Group Co., Ltd&#8230;.<\/p>\n","protected":false},"author":1,"featured_media":40077,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[945,15,2311,12,2828],"class_list":["post-40076","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-hkg-1099","tag-product-approvals","tag-sinopharm-group-company","tag-vaccine","tag-wuhan-institute-of-biological-products"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Wusheng\u202fErlunbao: Sinopharm\u2019s First\u2011of\u2011Its\u2011Kind Hexavalent Rotavirus Vaccine Receives NMPA Approval - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The Wuhan Institute of Biological Products Co., Ltd., a subsidiary of Sinopharm Group Co., Ltd. (HKG: 1099), has secured National Medical Products Administration (NMPA) clearance for its oral hexavalent reassortant rotavirus attenuated live vaccine\u2014traded under the name Wusheng\u202fErlunbao. This marks the first and most comprehensive rotavirus vaccine in the world, classified as a Category\u202f1 preventive biological product in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40076\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Wusheng\u202fErlunbao: Sinopharm\u2019s First\u2011of\u2011Its\u2011Kind Hexavalent Rotavirus Vaccine Receives NMPA Approval\" \/>\n<meta property=\"og:description\" content=\"The Wuhan Institute of Biological Products Co., Ltd., a subsidiary of Sinopharm Group Co., Ltd. (HKG: 1099), has secured National Medical Products Administration (NMPA) clearance for its oral hexavalent reassortant rotavirus attenuated live vaccine\u2014traded under the name Wusheng\u202fErlunbao. This marks the first and most comprehensive rotavirus vaccine in the world, classified as a Category\u202f1 preventive biological product in China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40076\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-26T05:45:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2606.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40076#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40076\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Wusheng\u202fErlunbao: Sinopharm\u2019s First\u2011of\u2011Its\u2011Kind Hexavalent Rotavirus Vaccine Receives NMPA Approval\",\"datePublished\":\"2025-08-26T05:45:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40076\"},\"wordCount\":272,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40076#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2606.webp\",\"keywords\":[\"HKG: 1099\",\"Product approvals\",\"Sinopharm Group Company\",\"Vaccine\",\"Wuhan Institute of Biological Products\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40076#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40076\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40076\",\"name\":\"Wusheng\u202fErlunbao: Sinopharm\u2019s First\u2011of\u2011Its\u2011Kind Hexavalent Rotavirus Vaccine Receives NMPA Approval - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40076#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40076#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2606.webp\",\"datePublished\":\"2025-08-26T05:45:31+00:00\",\"description\":\"The Wuhan Institute of Biological Products Co., Ltd., a subsidiary of Sinopharm Group Co., Ltd. (HKG: 1099), has secured National Medical Products Administration (NMPA) clearance for its oral hexavalent reassortant rotavirus attenuated live vaccine\u2014traded under the name Wusheng\u202fErlunbao. This marks the first and most comprehensive rotavirus vaccine in the world, classified as a Category\u202f1 preventive biological product in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40076#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40076\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40076#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2606.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2606.webp\",\"width\":1080,\"height\":608,\"caption\":\"Wusheng\u202fErlunbao: Sinopharm\u2019s First\u2011of\u2011Its\u2011Kind Hexavalent Rotavirus Vaccine Receives NMPA Approval\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40076#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Wusheng\u202fErlunbao: Sinopharm\u2019s First\u2011of\u2011Its\u2011Kind Hexavalent Rotavirus Vaccine Receives NMPA Approval\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Wusheng\u202fErlunbao: Sinopharm\u2019s First\u2011of\u2011Its\u2011Kind Hexavalent Rotavirus Vaccine Receives NMPA Approval - Insight, China&#039;s Pharmaceutical Industry","description":"The Wuhan Institute of Biological Products Co., Ltd., a subsidiary of Sinopharm Group Co., Ltd. (HKG: 1099), has secured National Medical Products Administration (NMPA) clearance for its oral hexavalent reassortant rotavirus attenuated live vaccine\u2014traded under the name Wusheng\u202fErlunbao. This marks the first and most comprehensive rotavirus vaccine in the world, classified as a Category\u202f1 preventive biological product in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40076","og_locale":"en_US","og_type":"article","og_title":"Wusheng\u202fErlunbao: Sinopharm\u2019s First\u2011of\u2011Its\u2011Kind Hexavalent Rotavirus Vaccine Receives NMPA Approval","og_description":"The Wuhan Institute of Biological Products Co., Ltd., a subsidiary of Sinopharm Group Co., Ltd. (HKG: 1099), has secured National Medical Products Administration (NMPA) clearance for its oral hexavalent reassortant rotavirus attenuated live vaccine\u2014traded under the name Wusheng\u202fErlunbao. This marks the first and most comprehensive rotavirus vaccine in the world, classified as a Category\u202f1 preventive biological product in China.","og_url":"https:\/\/flcube.com\/?p=40076","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-26T05:45:31+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2606.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40076#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40076"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Wusheng\u202fErlunbao: Sinopharm\u2019s First\u2011of\u2011Its\u2011Kind Hexavalent Rotavirus Vaccine Receives NMPA Approval","datePublished":"2025-08-26T05:45:31+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40076"},"wordCount":272,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40076#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2606.webp","keywords":["HKG: 1099","Product approvals","Sinopharm Group Company","Vaccine","Wuhan Institute of Biological Products"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40076#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40076","url":"https:\/\/flcube.com\/?p=40076","name":"Wusheng\u202fErlunbao: Sinopharm\u2019s First\u2011of\u2011Its\u2011Kind Hexavalent Rotavirus Vaccine Receives NMPA Approval - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40076#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40076#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2606.webp","datePublished":"2025-08-26T05:45:31+00:00","description":"The Wuhan Institute of Biological Products Co., Ltd., a subsidiary of Sinopharm Group Co., Ltd. (HKG: 1099), has secured National Medical Products Administration (NMPA) clearance for its oral hexavalent reassortant rotavirus attenuated live vaccine\u2014traded under the name Wusheng\u202fErlunbao. This marks the first and most comprehensive rotavirus vaccine in the world, classified as a Category\u202f1 preventive biological product in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40076#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40076"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40076#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2606.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2606.webp","width":1080,"height":608,"caption":"Wusheng\u202fErlunbao: Sinopharm\u2019s First\u2011of\u2011Its\u2011Kind Hexavalent Rotavirus Vaccine Receives NMPA Approval"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40076#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Wusheng\u202fErlunbao: Sinopharm\u2019s First\u2011of\u2011Its\u2011Kind Hexavalent Rotavirus Vaccine Receives NMPA Approval"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2606.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40076","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40076"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40076\/revisions"}],"predecessor-version":[{"id":40078,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40076\/revisions\/40078"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40077"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40076"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40076"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40076"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}